Nevro Corp.

NYSE:NVRO Stock Report

Market Cap: US$158.9m

Nevro Valuation

Is NVRO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NVRO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NVRO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NVRO's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NVRO?

Key metric: As NVRO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NVRO. This is calculated by dividing NVRO's market cap by their current revenue.
What is NVRO's PS Ratio?
PS Ratio0.4x
SalesUS$419.15m
Market CapUS$158.88m

Price to Sales Ratio vs Peers

How does NVRO's PS Ratio compare to its peers?

The above table shows the PS ratio for NVRO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3x
ARAY Accuray
0.4x5.5%US$185.0m
PDEX Pro-Dex
2.7x5.8%US$147.4m
KRMD KORU Medical Systems
5.2x14.7%US$151.8m
SRTS Sensus Healthcare
3.5x17.0%US$146.5m
NVRO Nevro
0.4x2.5%US$158.9m

Price-To-Sales vs Peers: NVRO is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (3x).

Price to Sales Ratio vs Industry

How does NVRO's PS Ratio compare vs other companies in the US Medical Equipment Industry?

52 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.3.2x8.2%
NVRO Nevro
 0.4x2.5%US$158.88m
INGN Inogen
0.7x4.2%US$226.04m
ARAY Accuray
0.4x5.5%US$185.04m
NVRO 0.4xIndustry Avg. 3.2xNo. of Companies52PS02.85.68.411.214+
52 CompaniesEstimated GrowthMarket Cap
Industry Avg.3.2x17.1%
NVRO Nevro
 0.4x3.4%US$158.88m
No more companies

Price-To-Sales vs Industry: NVRO is good value based on its Price-To-Sales Ratio (0.4x) compared to the US Medical Equipment industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is NVRO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NVRO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.4x
Fair PS Ratio1.2x

Price-To-Sales vs Fair Ratio: NVRO is good value based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (1.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NVRO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$4.23
US$7.05
+66.6%
32.9%US$13.00US$4.00n/a11
Nov ’25US$5.53
US$7.23
+30.7%
31.7%US$13.00US$4.00n/a11
Oct ’25US$5.23
US$7.59
+45.1%
29.3%US$13.00US$4.00n/a11
Sep ’25US$6.19
US$7.49
+21.0%
29.0%US$13.00US$4.00n/a12
Aug ’25US$9.18
US$14.09
+53.4%
53.6%US$40.00US$8.20n/a14
Jul ’25US$8.61
US$14.80
+71.9%
47.9%US$40.00US$9.00n/a15
Jun ’25US$9.35
US$14.80
+58.3%
47.9%US$40.00US$9.00n/a15
May ’25US$10.41
US$17.73
+70.3%
35.2%US$40.00US$14.00n/a15
Apr ’25US$13.32
US$19.40
+45.6%
30.1%US$40.00US$14.00n/a15
Mar ’25US$14.22
US$19.40
+36.4%
30.1%US$40.00US$14.00n/a15
Feb ’25US$17.22
US$21.44
+24.5%
30.5%US$40.00US$15.00n/a16
Jan ’25US$21.52
US$21.28
-1.1%
32.9%US$40.00US$13.00n/a16
Dec ’24US$18.82
US$20.09
+6.8%
38.2%US$40.00US$13.00n/a16
Nov ’24US$14.60
US$25.63
+75.6%
40.1%US$57.00US$17.00US$5.5315
Oct ’24US$19.22
US$28.40
+47.8%
33.4%US$57.00US$19.00US$5.2315
Sep ’24US$20.39
US$28.40
+39.3%
33.4%US$57.00US$19.00US$6.1915
Aug ’24US$24.67
US$35.87
+45.4%
41.0%US$75.00US$24.00US$9.1815
Jul ’24US$25.42
US$37.57
+47.8%
39.3%US$75.00US$24.00US$8.6114
Jun ’24US$27.43
US$41.07
+49.7%
35.4%US$76.00US$29.00US$9.3514
May ’24US$28.31
US$42.83
+51.3%
35.0%US$76.00US$31.00US$10.4112
Apr ’24US$36.15
US$44.91
+24.2%
31.1%US$75.00US$33.00US$13.3211
Mar ’24US$31.61
US$44.91
+42.1%
31.1%US$75.00US$33.00US$14.2211
Feb ’24US$37.15
US$44.82
+20.6%
28.6%US$75.00US$33.00US$17.2211
Jan ’24US$39.60
US$48.00
+21.2%
26.5%US$75.00US$31.00US$21.5211
Dec ’23US$47.90
US$48.09
+0.4%
26.1%US$75.00US$31.00US$18.8211
Nov ’23US$39.30
US$53.00
+34.9%
28.0%US$86.00US$31.00US$14.6011

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

CVS Health

US$70.2b

Provides health solutions in the United States.

CVS

US$56.83

7D

4.7%

1Y

-17.8%

Centene

US$29.2b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$59.10

7D

1.8%

1Y

-20.4%

Elevance Health

US$91.4b

Operates as a health benefits company in the United States.

ELV

US$397.48

7D

-3.3%

1Y

-17.2%